Regeneron Pharmaceuticals v. Sanofi Biotechnology SAS

Request

Regeneron Pharmaceuticals, Inc. and Sanofi Biotechnology SAS, Sanofi S.A., sanofi-aventis U.S. LLC, and Genzyme Corporation asked the court to approve filing a redacted version of the transcript from a June 5, 2025 conference. The request concerned the transcript filed as Document 58. The parties proposed that the redacted transcript be filed publicly as Document 63 and that the unredacted versions, identified as Documents 58 and 62, remain under seal.

Reason for the Request

The parties said the transcript contained confidential information about an agreement between Regeneron and Sanofi, including nonpublic dispute-resolution terms. They argued that disclosure could harm the parties in future contract negotiations and could provide useful information to potential business partners or pharmacy benefit managers involved in pricing negotiations. They also argued that the public benefit from disclosing those terms would be minimal.

The request cited the court's authority to control access to its records and the Second Circuit's balancing test for sealing judicial documents. Under that approach, courts weigh the public's presumptive right to access court records against competing interests, including protecting sensitive, competitive, or proprietary business information.

Ruling

Judge Philip M. Halpern granted the application. The redacted transcript, Document 63, shall remain the publicly filed version of the transcript, and the unredacted versions, Documents 58 and 62, shall remain under seal. The order does not otherwise describe or resolve the underlying dispute between Regeneron and the Sanofi defendants.